文献速递糖尿病垂体与肾上腺疾病

终末期肾病与肾功能保留患者糖尿病酮症酸中毒的生化参数差异

Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该观察性研究纳入2006至2016年Emory大学医院收治的18-80岁糖尿病酮症酸中毒(DKA)成人,比较终末期肾病(ESKD)、中度肾衰竭和肾功能保留三组的生化参数。结果显示三组入院碳酸氢盐和pH相似,但ESKD组β-羟丁酸更低、血糖和阴离子间隙更高,且β-羟丁酸>3 mmol/L有助于ESKD患者DKA诊断。

要点

  • ESKD合并DKA患者β-羟丁酸水平低于肾功能保留者,但血糖和阴离子间隙更高。
  • 三组入院碳酸氢盐和pH无显著差异,代谢性酸中毒程度相似。
  • ESKD患者β-羟丁酸>3 mmol/L对DKA诊断具有较高敏感性。

核心结论

  • 不同肾功能水平的DKA患者存在显著代谢差异。
  • ESKD患者β-羟丁酸>3 mmol/L可能辅助确认DKA诊断。

研究设计与样本

  • DKA和肾功能分期基于入院实验室检查确认。

主要发现

  • 三组入院碳酸氢盐(13.9±5 vs 13.4±5.3 vs 13.8±4.2 mmol/L,P=0.7)和pH(7.2±0.3 vs 7.2±0.2 vs 7.2±0.2,P=0.8)相似。
  • ESKD组平均β-羟丁酸水平更低(4.3±3.3 vs 5.6±2.9 vs 5.9±2.5 mmol/L,P=0.01)。
  • ESKD组入院血糖(852±340.4 vs 714.6±253.3 vs 518±185.7 mg/dL,P<0.01)、阴离子间隙(23.4±7.6 vs 23±6.9 vs 19.5±4.7 mmol/L,P<0.01)和渗透压(306±20.6 vs 303.5± vs 293.1±3.1 mOsm/kg,P<0.01)更高。
  • β-羟丁酸>3 mmol/L诊断DKA的敏感性(按碳酸氢盐<15和<18 mmol/L):ESKD组86.9%和72%,中度肾衰竭组89.3%和83.7%,肾功能保留组96.2%和88.3%。
  • ESKD患者碳酸氢盐<10、10-15、<18 mmol/L对应的β-羟丁酸分别为5.5、3.9、3.0 mmol/L。

关键数值与推荐

  • ESKD定义为eGFR<15 mL/min/1.73 m2,中度肾衰竭为eGFR 15-60,肾功能保留为eGFR>60。
  • ESKD患者β-羟丁酸>3 mmol/L可辅助DKA诊断。

临床怎么用

  • 对于ESKD合并DKA疑似患者,β-羟丁酸>3 mmol/L可支持诊断。
  • 需注意ESKD患者β-羟丁酸水平可能相对较低,但血糖和阴离子间隙更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Differences in biochemical parameters of diabetic ketoacidosis in patients with end-stage kidney disease (ESKD) has not been established. Accordingly, we assessed the relationship between degree of metabolic acidosis and ß-hydroxybutyrate in patients with ESKD (eGFR < 15 mL/min/1.73 m2), moderate renal failure (eGFR 15-60), or preserved renal function (eGFR > 60). METHODS: This observational study included adults (18-80 years) with diabetes ketoacidosis (DKA), admitted to Emory University Hospitals between January 1, 2006 to December 31, 2016. DKA and renal stages were confirmed on admission laboratory values. RESULTS: Admission bicarbonate levels (13.9 ± 5 vs 13.4 ± 5.3 vs 13.8 ± 4.2 mmol/L, P = 0.7), and pH levels (7.2 ± 0.3 vs 7.2 ± 0.2 vs 7.2 ± 0.2, P = 0.8) were similar among groups. Patients with ESKD had lower mean ß-hydroxybutyrate level (4.3 ± 3.3 vs 5.6 ± 2.9 vs 5.9 ± 2.5 mmol/L, P = 0.01), but higher admission glucose (852 ± 340.4 vs 714.6 ± 253.3 mg/dL vs 518 ± 185.7 mg/dL, P < 0.01), anion gap (23.4 ± 7.6 vs 23 ± 6.9 vs 19.5 ± 4.7 mmol/L, P < 0.01), and osmolality (306 ± 20.6 vs 303.5 ± vs 293.1 ± 3.1mOsm/kg, P < 0.01) compared with patients with moderate renal failure and preserved renal function, respectively. The sensitivity of ß-hydroxybutyrate > 3 mmol/L for diagnosing DKA by bicarbonate level < 15 and <18 mmol/L was 86.9% and 72% in ESKD, 89.3% and 83.7% in moderate renal failure, and 96.2% and 88.3% in preserved renal function. In patients with ESKD, the corresponding ß-hydroxybutyrate with bicarbonate levels < 10, 10-15, <18 mmol/L were 5.5, 3.9, 3.0 mmol/L, respectively. CONCLUSIONS: Significant metabolic differences were found among DKA patients with different levels of renal function. In patients with ESKD, a ß-hydroxybutyrate level > 3 mmol/L may assist with confirmation of DKA diagnosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Galindo RJ, Pasquel FJ, Vellanki P, et al. Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function. J Clin Endocrinol Metab. 2021. PMID: 33659978. doi:10.1210/clinem/dgab126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。